目的 观察对比增强CT(contrast-enhanced CT, CECT)中对比剂对原发性肝癌受检者肾功能及免疫球蛋白的影响。方法 选择2013-08至2014-04在我院接受CECT检查的患者54例,选取肝功能Child-pugh A级的原发性肝癌34例为观察组,肝血管瘤20例为对照组,两组受检者均首次静脉注射碘海醇行CECT检查,分别于检查前及检查后24 h测定尿比重(specific gravity,SG)、pH值、微量白蛋白(microalbumin, MAU)和血尿素氮(BUN)、肌酐(Scr)、尿酸(UA)、β2微球蛋白(β2MG)、胱抑素C(CysC)、C-反应蛋白(CRP)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM),采用配对检验比较检查前、后各指标的变化。结果 CECT检查后,所有受检者pH、MAU显著升高,观察组IgM由(1.09±0.42)g/L下降为(0.92±0.34)g/L,对照组IgM由(1.12±0.43)g/L下降为(0.91±0.31)g/L;观察组的β2MG由(1.68±0.73)mg/L显著升高为(1.99±0.64)mg/L,差异具有统计学意义(P＜0.05)。而SG、BUN、Scr、CysC、CRP、IgA、IgG差异无统计学意义。结论 CECT中对比剂对原发性肝癌患者的肾功能及免疫功能具有一定的损害作用。
Abstract
Objective To study the acute kidney injury and immunoglobulins changes in the hepatocellulor carcinoma patients who underwent contrast-enhanced CT (CECT) examination. Methods A total of 54 patients(34 primary hepatic carcinoma patients and 20 hepatic hemangioma patients) were included in this study who underwent CECT examination. The individual information was collected from each patient. Then we examined the level of SG,pH and MAU in urine, and the level of BUN,Scr,β2MG,Cysc,CRP,IgA,IgG and IgM in serum before and after 24 hours CECT examination respectively. Results After CECT examination, all the patients’ level of pH,MAU and the primary hepatic carcinoma patients’ level of β2MG were much higher than those of before, while the IgM level of all the patients reduced significantly, the difference was statistically significant (P<0.05). However, the changes in SG,BUN,Scr,Cysc,CRP,IgA and IgG had no significant difference. Conclusions Contrast media may lead renal function and immune system damage to the hepatocellulor carcinoma patients who undergo CECT.
关键词
对比增强CT /
对比剂 /
肾功能不全 /
免疫功能
Key words
contrast-enhanced CT /
contrast media /
kidney insufficiency /
immune function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 张保翠,张玉东,赵 凯,等.静脉注射碘对比剂对不同人群肾功能的影响[J].中华放射学杂志,2013,47(4):335-339.
[2] Lodhia N, Kader M, Mayes T, et al. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis[J].World J Gastroenterol,2009,15(12):1459-1464.
[3] 黄文福,马德亮,周和平.对比剂对肝功能的影响[J].临床荟萃,2011,26(21):1882-1883.
[4] 黄文福,彭辽宇,梁世伟.碘海醇增强CT对受检者血细胞及血液流变学的影响[J].临床误诊误治,2013, 26(5):66-67.
[5] Mitchell A M, Jones A E, Tumlin J A,et al. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting[J].Clin J Am Soc Nephrol,2010,5(1):4-9.
[6] Heyman S N, Rosen S, Khamaisi M, et al.Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy[J].Invest Radiol,2010,45(4):188-195.
[7] 缪黄泰,聂绍平.CT相关造影剂肾病[J].中华实用诊断与治疗杂志,2013,27(11):1041-1043.
[8] Ledermann H P, Mengiardi B, Schmid A, et al. Screening for renal insufficiency following ESUR (European Society of Urogenital Radiology) guidelines with on-site creatinine measurements in an outpatient setting[J].Eur Radiol, 2010,20(8):1926-1933.
[9] 王 冰,郭兴来,高 勇.血清胱抑素C尿β2微球蛋白和尿微量白蛋白联合检测在恶性肿瘤患者早期肾功能损害中的应用[J].安徽医学,2013,34(12):1840-1843.
[10] 张 翩,王 玲,倪兆慧,等.尿液中性粒细胞明胶酶相关载脂蛋白应用于早期诊断对比剂肾病的价值[J].上海医学,2013,36(3):194-199.
[11] Koyner J L, Garg A X, Shlipak M G, et al. Urinary cystatin C and acute kidney injury after cardiac surgery[J].Am J Kidney Dis,2013,61(5):730-738.
[12] 赵峰波,郭加旺,刘勇志,等.血清β2微球蛋白、胱抑素C在评价早期肾功能损伤中的敏感性[J].实用临床医药杂志,2013,17(21):157-158.
[13] 张 静,王海屹,叶慧义.肝脏特异性对比剂Gd-EOB-DTPA对正常肝脏及其肿瘤ADC值的影响[J].武警医学,2013,24(8):699-702.
[14] 陈 曦,李 军,姜小飞,等.对比剂对大鼠肾进球小管钠钾ATP酶活性的影响[J].广东医学,2011,32 (11):1405-1407.
[15] 王文龙,高海燕,于秀艳.血清β2微球蛋白和多肿瘤标志物在非霍奇金淋巴瘤中的临床意义[J].中国实验诊断学,2013,17(7):1330-1331.
[16] 纪芳杰,丛洪良,杨世诚,等.强化阿托伐他汀治疗对高血压合并慢性肾功能不全患者经皮冠状动脉介入治疗后对比剂肾病的预防作用[J].中华高血压杂志,2013,21(6):577-581.
[17] 杜 敏,马淑梅.造影剂肾病[J].实用药物与临床,2009,12(1):55-58.
PDF(555 KB)
